<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
November 30, 1999
ALBANY MOLECULAR RESEARCH, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-25323 14-1742717
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification No.)
21 Corporate Circle
Albany, New York 12203
(Address of principal executive offices)
(518) 464-0279
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events.
On October 19, 1999, Albany Molecular Research, Inc. (the "Company") consummated
a merger of EnzyMed, Inc. ("EnzyMed") with and into the Company pursuant to an
Agreement and Plan of Merger dated as of September 8, 1999. The Company is
filing this Current Report on Form 8-K to publish unaudited financial results
covering 30 days of combined operations of the Company and EnzyMed following the
merger. Selected unaudited financial results of the Company for the 30 days
ended November 30, 1999 are as follows:
<TABLE>
<S> <C>
Net contract revenue $ 2,228,903
Net income available for common shareholders 1,047,895
Basic net income per share $ 0.07
Diluted net income per share 0.07
Weighted average shares outstanding
Basic 14,580,651
Diluted 15,338,494
</TABLE>
Month to month fluctuations in operating results may be substantial due to,
among other things, the initiation, cancellation or completion of contracts;
the integration of the Company's acquisitions; and estimates of royalties due
the Company related to Telfast/Allegra. Therefore, monthly results are not
necessarily indicative of results for a full quarter.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ALBANY MOLECULAR RESEARCH, INC.
Date: December 23, 1999 By: /s/ David P. Waldek
----------------------
David P. Waldek
Chief Financial Officer
